Gilead Sciences
- All
- News
- Videos
-
Revolutionary New Drug Offers 99.9% Protection Against HIV
The US FDA has approved lenacapavir, a groundbreaking long-acting HIV prevention drug that offers near-complete protection with just two injections per year. Despite its potential, concerns about high costs may limit its global impact.
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
WHO Says No Evidence Remdesivir Improves Survival, Gilead "Disappointed"
The World Health Organization recommended against using Gilead Sciences Inc.'s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval.
-
Nations Eyeing Gilead's Covid Drug Should Take Note Of Failed Trial: WHO
Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
-
WHO Defends Data After Concluding Gilead's Remdesivir Flopped Covid Trial
A World Health Organization (WHO) trial that concluded Gilead Sciences Inc.'s remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated the data said on Friday, as the U.S. company criticized its methodology.
-
Remdesivir Didn't Cut Hospital Stay Or Mortality In Covid Patients: WHO
Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
-
Gilead Seeks US Approval For Drug That Shortens Covid Recovery Time
Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.
-
Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk
Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
-
Revolutionary New Drug Offers 99.9% Protection Against HIV
The US FDA has approved lenacapavir, a groundbreaking long-acting HIV prevention drug that offers near-complete protection with just two injections per year. Despite its potential, concerns about high costs may limit its global impact.
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
WHO Says No Evidence Remdesivir Improves Survival, Gilead "Disappointed"
The World Health Organization recommended against using Gilead Sciences Inc.'s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval.
-
Nations Eyeing Gilead's Covid Drug Should Take Note Of Failed Trial: WHO
Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
-
WHO Defends Data After Concluding Gilead's Remdesivir Flopped Covid Trial
A World Health Organization (WHO) trial that concluded Gilead Sciences Inc.'s remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated the data said on Friday, as the U.S. company criticized its methodology.
-
Remdesivir Didn't Cut Hospital Stay Or Mortality In Covid Patients: WHO
Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
-
Gilead Seeks US Approval For Drug That Shortens Covid Recovery Time
Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.
-
Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk
Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
